Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRTX849 (Adagrasib) vs Docetaxel in Previously Treated NSCLC With KRAS G12C Mutation
NCT04685135Phase 3Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Feb 2021; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04685135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685135.